Brief: Fredun Pharmaceuticals Sees Fy26 EBITDA Margins At 12%-15%
21/02/2023 13:43
Feb 21 (Reuters) - Fredun Pharmaceuticals Ltd FRED.BO :
* SEES FY26 EBITDA MARGINS AT 12%-15%
Source text for Eikon: ID:nBSE2WwqMg
Further company coverage: FRED.BO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fredun Pharmaceuticals
See all newsBrief: Fredun Pharmaceuticals March-Quarter Consol Profit 107.8 Million Rupees
Brief: Fredun Pharmaceuticals Expands Manufacturing Base With Fifth Facility At Palghar
Brief: Fredun Pharmaceuticals Dec-Quarter Consol Profit 104.8 Million Rupees
Brief: Fredun Pharmaceuticals To Issue 652,360 Equity Shares
Brief: Fredun Pharmaceuticals Receives SEBI Adjudication Order